tetano
Editor, Senior Moderator
While the epidemic of influenza probably attained its peak for this year, study FluMeD is going to make out a will on two seasons of influenzal epidemic (on 2011-2012 and 2012-2013), the hydrochloride of midodrine, an already available medicament to treat low blood pressure... ? The objective of this try is to confirm the anti-influenzal action of this cure noticed in vitro and to enlarge so the therapeutic indication of this molecule ? the recent press release of Inserm points out.
The laboratory VirPath aimed by Pr. Bruno Lina in Lyons, in partnership with Inserm, works since 2008 on the identification of new anti-influenzal molecules in the original mode of action.
Let us say that nowadays, antiviral available block viral proteins specifically to restrict replication and spread of the virus in organism. But this strategy collides with the problem of the big changeability of viruses. It is case this year for instance: one of the viruses evolved, making the vaccine of this season a little less efficient ?
? A treatment exercises a pressure of selection over the virus which mutates fast and becomes so resistant ?, the Dr insists. Manuel Rosa-Calatrava (Inserm), co-author of jobs. In this title, its team (VirCell) worked on a new approach: which target the oblique cell ways of signalling by the viruses of influenza and return the cells of the guest favourable to the infection, then identify already existent molecules which would block the ways of signalling being discussed.
At first, the team of the Dr. Rosa-Calatrava* worked on human pulmonary epithelial cell cultures infected by different viruses of the influenza of type A human (H1N1 AND H3N2) and aviaires (H5N1, H5N2 AND H7N7).
http://www.senioractu.com/Grippe-un...ge-spectre-actuellement-a-l-essai_a14682.html
The laboratory VirPath aimed by Pr. Bruno Lina in Lyons, in partnership with Inserm, works since 2008 on the identification of new anti-influenzal molecules in the original mode of action.
Let us say that nowadays, antiviral available block viral proteins specifically to restrict replication and spread of the virus in organism. But this strategy collides with the problem of the big changeability of viruses. It is case this year for instance: one of the viruses evolved, making the vaccine of this season a little less efficient ?
? A treatment exercises a pressure of selection over the virus which mutates fast and becomes so resistant ?, the Dr insists. Manuel Rosa-Calatrava (Inserm), co-author of jobs. In this title, its team (VirCell) worked on a new approach: which target the oblique cell ways of signalling by the viruses of influenza and return the cells of the guest favourable to the infection, then identify already existent molecules which would block the ways of signalling being discussed.
At first, the team of the Dr. Rosa-Calatrava* worked on human pulmonary epithelial cell cultures infected by different viruses of the influenza of type A human (H1N1 AND H3N2) and aviaires (H5N1, H5N2 AND H7N7).
http://www.senioractu.com/Grippe-un...ge-spectre-actuellement-a-l-essai_a14682.html